ClinicalTrials.Veeva

Menu

Mechanisms and Factors Responsible for the Inhibition of Transposons During Fetal Gonad Development in Humans

U

University Hospital Center (CHU) Dijon Bourgogne

Status

Enrolling

Conditions

Voluntary Termination of Pregnancy
Medical Termination of Pregnancy

Treatments

Other: surgical biopsies

Study type

Observational

Funder types

Other

Identifiers

NCT02171845
FAUQUE ANR 2011

Details and patient eligibility

About

This is a single-centre study over 36 months for the inclusion of 30 patients. The selection and inclusion of patients will take place according to the criterion of Medical Termination of Pregnancy at 4 different gestational ages (8-12 weeks of gestation (WG)), 13-16 WG, 17-23 WG and 25-35 WG. The tissue analysed will principally be the gonads, other somatic tissue will also be systematically harvested in parallel (liver and psoas muscle) for control purposes. The gonads will be subjected to molecular biology analyses destined to quantify the expression of transposons and their inhibitors.

Enrollment

30 estimated patients

Sex

Male

Ages

10 to 37 weeks old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Couple or mother who has provided written informed consent
  • Foetus between 10 and 37 weeks of amenorrhea (WA)
  • Male foetus
  • Foetus obtained following medical termination of pregnancy or voluntary termination of pregnancy

Exclusion criteria

  • persons without national health insurance cover
  • foetus presenting aneuploidy
  • foetus presenting a malformation of the genital organs

Trial design

30 participants in 1 patient group

Foetus
Treatment:
Other: surgical biopsies

Trial contacts and locations

1

Loading...

Central trial contact

Patricia FAUQUE

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems